We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2003;289(20):2611. doi:10.1001/jama.289.20.2611.
Text Size: A A A
Published online


New findings from the Women‘s Health Initiative (WHI) challenge previous evidence that suggested that estrogen-containing hormone therapy has a protective effect on the brain in postmenopausal women. In the estrogen plus progestin component of the WHI Memory Study (WHIMS), which included women aged 65 years or older enrolled in the WHI trial, Shumaker and colleaguesArticle found that the risk of probable dementia in the estrogen plus progestin group was twice that in the placebo group during a mean follow-up of 4 years. Rapp and colleaguesArticle also report that although most women in WHIMS did not experience a clinically important decline in global cognitive function, more women in the estrogen plus progestin group than in the placebo group had a substantial decline in cognitive function. Wassertheil-Smoller and colleaguesArticle, in additional analyses of data from the WHI trial, found that the risk of stroke, particularly ischemic stroke, was significantly increased in the estrogen plus progestin group overall and in a number of subgroups of women. In an editorial, YaffeArticle considers possible explanations for the discrepancies between results of observational studies of hormone therapy and those of the WHI randomized trial.


The most common modes of death for patients with heart failure are sudden cardiac death from ventricular arrhythmias and progressive heart failure. Young and colleaguesArticle conducted a randomized trial among patients with moderate-to-severe heart failure and wide QRS interval to evaluate combining an implantable cardioverter defibrillator (ICD) with cardiac resynchronization therapy (CRT), which would provide both defibrillation and resynchronization capabilities. All patients underwent implantation with a combined defibrillation-resynchronization device and had the cardioverter-defibrillator function activated throughout the trial. Improvements in quality of life, functional class, and exercise capacity were significantly greater among patients who had active CRT and ICD than among those with active ICD alone. CRT did not interfere with cardioverter-defibrillator function. In an editorial, BradleyArticle points out several caveats to consider when applying the results of this study to patients who may be candidates for combined resynchronization-defibrillation therapy.


Many prostate cancers detected using serum prostate-specific antigen (PSA) screening are clinically insignificant, and it is not clear whether early detection of prostate cancer using PSA screening reduces prostate cancer mortality. Eastham and colleagues conducted PSA testing on consecutive annual blood samples from an unscreened cohort of men participating in the Polyp Prevention Trial. Among men with an abnormal PSA test result, 40% to 55%, depending on the cutoff level for an abnormal PSA result, had a normal PSA finding at 1 or more subsequent visits during 4 years of follow-up.

See Article


Mrs W visited a physician after 1 day of cold symptoms, concerned about spreading her illness to family members. The physician diagnosed viral acute respiratory infection but prescribed an antibiotic at the patient's insistence. Gonzales discusses the evaluation and treatment of acute respiratory infections and risks of unnecessary antibiotic use.

See Article


"That smart funny quirky slightly crazy brilliant light has been snuffed out, destroyed, lost forever, and nothing will ever be the same again." From "What I Have Seen."

See Article


A novel program in North Carolina using HIV RNA screening to detect acute HIV infections could help health officials identify early clusters and target interventions.

See Article


Major challenges in writing about race and ethnicity in biomedical publications and recommendations to address them.

See Article


For your patients: Information about the common cold.

See Article



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.